Shaping a high-mass star-forming cluster through stellar feedback. The case of the NGC 7538 IRS 1-3 complex

Context: NGC 7538 IRS 1-3 is a high-mass star-forming cluster with several detected dust cores, infrared sources, (ultra)compact H$_{\rm II}$ regions, molecular outflows, and masers. In such a complex environment, important interactions and feedback among the embedded objects are expected to play a major role in the evolution of the region. Aims: We study the dust, kinematic, and polarimetric properties of the NGC 7538 IRS 1-3 region to investigate the role of the different forces interplaying in the formation and evolution of high-mass star-forming clusters. Methods: We perform SMA high angular resolution observations at 880 $\mu$m with the compact configuration. We develop the RATPACKS code to generate synthetic velocity cubes from models of choice to be compared to the observational data. We develop the "mass balance" analysis to quantify the stability against gravitational collapse accounting for all the energetics at core scales. Results: We detect 14 dust cores from 3.5 $M_{\odot}$ to 37 $M_{\odot}$ arranged in two larger scale structures: a central bar and a filamentary spiral arm. The spiral arm presents large scale velocity gradients in H$^{13}$CO$^+$ 4-3 and C$^{17}$O 3-2, and magnetic field segments well aligned to the dust main axis. The velocity gradient is well reproduced by a spiral arm expanding at 9 km s$^{-1}$ with respect to the central core MM1, which is known to power a large precessing outflow. The energy of the outflow is comparable with the spiral arm kinetic energy, which is dominant over gravitational and magnetic energies. In addition, the dynamical ages of the outflow and spiral arm are comparable. ... (Full abstract in the pdf version)Comment: 15 pages, 9 figures, 4 tables. Accepted for publication in A&

Low-density lipoprotein cholesterol lowering therapies: what is on the horizon?

Elevated low-density lipoprotein cholesterol (LDL-C) levels are associated with an increased risk for cardiovascular disease (CVD). Statins have been the cornerstone of lipid therapy to lower LDL-C for the past two decades, but despite significant clinical efficacy in a majority of patients, a large residual risk remains for the development of initial or recurrent atherosclerotic CVD. In addition, owing to the side-effects, a significant percentage of patients cannot tolerate any statin dose or a high enough statin dose. Thus, novel therapeutic agents are currently being developed to lower LDL-C levels further. This review will highlight these novel therapeutic agents including antisense oligonucleotides focused on apolipoprotein B, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and microsomal triglyceride transfer protein inhibitors. For each therapeutic class, an overview of mechanism of action, pharmacokinetic data, and efficacy/safety evidence will be discussed

The magnetic field in the NGC 2024 FIR 5 dense core

We used the Submillimeter Array (SMA) to observe the thermal polarized dust emission from the protostellar source NGC 2024 FIR 5. The polarized emission outlines a partial hourglass morphology for the plane-of-sky component of the core magnetic field. Our data are consistent with previous BIMA maps, and the overall magnetic field geometries obtained with both instruments are similar. We resolve the main core into two components, FIR 5A and FIR 5B. A possible explanation for the asymmetrical field lies in depolarization effects due to the lack of internal heating from FIR 5B source, which may be in a prestellar evolutionary state. The field strength was estimated to be 2.2 mG, in agreement with previous BIMA data. We discuss the influence of a nearby H{\sc ii} region over the field lines at scales of $\sim 0.01$ pc. Although the hot component is probably compressing the molecular gas where the dust core is embedded, it is unlikely that the radiation pressure exceeds the magnetic tension. Finally, a complex outflow morphology is observed in CO (3 $\rightarrow$ 2) maps. Unlike previous maps, several features associated with dust condensations other than FIR 5 are detected.Comment: 48 pages, 12 figures, accepted for publication in The Astrophysical Journa

Ab Initio Green-Kubo Approach for the Thermal Conductivity of Solids

We herein present a first-principles formulation of the Green-Kubo method that allows the accurate assessment of the non-radiative thermal conductivity of solid semiconductors and insulators in equilibrium ab initio molecular dynamics calculations. Using the virial for the nuclei, we propose a unique ab initio definition of the heat flux. Accurate size- and time convergence are achieved within moderate computational effort by a robust, symptotically exact extrapolation scheme. We demonstrate the capabilities of the technique by investigating the thermal conductivity of extreme high and low heat conducting materials, namely diamond Si and tetragonal ZrO2

HDL-C: Does it matter? An update on novel HDL-directed pharmaco-therapeutic strategies.

It has long been recognized that elevated levels of low-density lipoprotein cholesterol (LDL-C) increase the risk of cardiovascular disease (CHD) and that pharmacologic therapy to decrease LDL-C significantly reduces cardiovascular events. Despite the effectiveness of statins for CHD risk reduction, even optimal LDL-lowering therapy alone fails to avert 60% to 70% of CHD cases. A low plasma concentration of high-density lipoprotein cholesterol (HDL-C) is also associated with increased risk of CHD. However, the convincing epidemiologic data linking HDL cholesterol (HDL-C) to CHD risk in an inverse correlation has not yet translated into clinical trial evidence supporting linearity between HDL-C increases and CHD risk reduction. It is becoming clear that a functional HDL is a more desirable target than simply increasing HDL-C levels. Discoveries in the past decade have shed light on the complex metabolic and antiatherosclerotic pathways of HDL. These insights, in turn, have fueled the development of new HDL-targeted drugs, which can be classified according to four different therapeutic approaches: directly augmenting the concentration of apolipoprotein A-I (apo A-I), the major protein constituent of HDL; indirectly augmenting the concentration of apo A-I and HDL cholesterol; mimicking the functionality of apo A-I and enhancing reverse cholesterol transport. This review discusses the latest in novel HDL directed therapeutic strategies